Prevalence and epidemiology of autoimmune hepatitis

Clinics in Liver Disease

Volumn 6, Issue 3, 2002, Pages 347-359

  Boberg, Kirsten Muri ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; HLA DR ANTIGEN;

AUTOIMMUNE HEPATITIS; CAUCASIAN; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ETHNOLOGY; GENETIC SUSCEPTIBILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MULTIPLE ENDOCRINE ADENOMATOSIS; PREVALENCE; RACE; REVIEW; SCLEROSING CHOLANGITIS;

ADOLESCENT; ADULT; AGED; ARGENTINA; AUTOANTIBODIES; CHILD; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS, AUTOIMMUNE; HLA-DR ANTIGENS; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NORTH AMERICA; PREVALENCE;

EID: 0036695544     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
2. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
3. Czaja AJ. Clinical aspects of autoimmune hepatitis in North America. In: Nishioka M, Toda G, Zeniya M, editors. Autoimmune hepatitis. Amsterdam, Elsevier; 1994. pp. 27-43.
4. Gordon SC. Diagnostic criteria, clinical manifestations and natural history of autoimmune hepatitis. In: Krawitt EL, Wiesner RH, Nishioka M, editors. Autoimmune liver diseases. 2nd edition. Amsterdam, Elsevier; 1998. pp. 343-360.
5. Johnson PJ, McFarlane IG, Eddleston ALWF. The natural course and heterogeneity of autoimmune-type chronic active hepatitis. Semin Liver Dis 1991;11:187-96.
6. McFarlane IG. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998;42:599-602.
7. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394-401.
8. Czaja AJ, Carpenter HA, Santrach PJ, et al. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993;104:1755-61.
9. Homberg J-C, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/ kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987; 7:1333-9.
10. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973;15:331-44.
11. Manns M, Gerken G, Kyriatsoulis A. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-4.
12. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355:1510-5.
13. Maddrey WC. Subdivisions of idiopathic autoimmune chronic active hepatitis. Hepatology 1987;7:1372-5.
14. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997;26:459-66.
15. Strassburg CP, Obermayer-Straub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000;18:127-39.
16. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
17. Czaja AJ, Carpenter HA. Validation of a scoring system for the diagnosis of autoimmune hepatitis. Dig Dis Sci 1996;41:305-14.
18. Hay JE, Czaja AJ, Rakela J, et al. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989;9:193-7.
19. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120:1502-17.
20. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol 1994;21:866-71.
21. Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children. In: Krawitt EL, Wiesner RH, Nishioka M, editors. Autoimmune liver diseases. 2nd edition. Amsterdam, Elsevier; 1998. pp. 425-432.
22. Ben-Ari Z, Czaja AJ. Autoimmune hepatitis and its variant syndromes. Gut 2001;49:589-94.
23. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-53.
24. Nishioka M, Morshed SA, McFarlane IG. Geographical variation in the frequency and characteristics of autoimmune liver diseases. In: Krawitt EL, Wiesner RH, Nishioka M, editors. Autoimmune liver diseases. 2nd edition. Amsterdam, Elsevier; 1998. pp. 413-424.
25. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9.
26. Czaja AJ, Manns MP, McFarlane IG, et al. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 2000;31:1194-200.
27. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
28. Hodges JR, Millward-Sadler GH, Wright R. Chronic active hepatitis: the spectrum of disease. Lancet 1982;1:550-2.
29. Bjarnason I, Magnusson B, Bjornsson S. Idiopathic chronic active hepatitis in Iceland. Acta Med Scand 1982;211:305-7.
30. Ritland S. The incidence of chronic active hepatitis in Norway. A retrospective study. Scand J Gastroenterol 1985;20(suppl 107):58-60.
31. Tanner AR, Dellipiani AW. Chronic active hepatitis: a sixteen year survey at a district general hospital. Postgrad Med J 1989;65:725-8.
32. Olsson R, Lindberg J, Weiland O, et al. Chronic active hepatitis in Sweden. The etiologic spectrum, clinical presentation, and laboratory profile. Scand J Gastroenterol 1988;23:463-70.
33. Lam KC, Lai CL, Wu PC, et al. Etiological spectrum of liver cirrhosis in the Chinese. J Chron Dis 1980;33:375-81.
34. Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan - correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 1997;26:1207-12.
35. Mackay IR, Morris PJ. Association of autoimmune active chronic hepatitis with HL-A1,8. Lancet 1972;2:793-5.
36. Cancado ELR, Porta G. Autoimmune hepatitis in South America. Falk Symposium 2000;114: 82-92.
37. Boberg KM, Aadland E, Jahnsen J, et al. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998;33:99-103.
38. Morshed SA, Parveen S, Nishioka M. Antibodies to cytoskeleton antigens in autoimmune liver diseases. In: Krawitt EL, Wiesner RH, Nishioka M, editors. Autoimmune liver diseases. 2nd edition. Amsterdam, Elsevier; 1998. pp. 217-256.
39. Gueguen M, Boniface O, Bernard O, et al. Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. J Autoimmun 1991;4:607-15.
40. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
41. Czaja AJ, Manns MP, Homburger HA. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 1992;103:1290-5.
42. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7.
43. Smith MGM, Williams R, Walker G, et al. Hepatic disorders associated with liver/kidney microsomal antibodies. BMJ 1974;2:80-4.
44. Manns MP. Cytoplasmic autoantigens in autoimmune hepatitis: molecular analysis and clinical relevance. Semin Liver Dis 1991;11:205-14.
45. Vogel W, Simma B, Meister B, et al. Autoimmune chronic active hepatitis associated with antibodies to liver cytosol in identical twins [abstract]. Hepatology 1993;18:220A.
46. Todros L, Touscoz G, D'Urso N, et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 1991;13:128-31.
47. Wozniak M, Pawlowska J, Homberg J-C, et al. Efficiency of treatment in children in relation to different type of autoimmune hepatitis - retrospective study. Hepatol Polska 1996;3:15-20.
48. Homberg J-C, Johanet C, Dubel L. Antibodies to endoplasmic reticulum and cytosol antigens in autoimmune hepatitis. In: Krawitt EL, Wiesner RH, Nishioka M, editors. Autoimmune liver diseases. 2nd edition. Amsterdam, Elsevier; 1998. pp. 257-272.
49. Lindgren S, Braun H-B, Michel G, et al. Absence of LKM-1 antibody reactivity in autoimmune and hepatitis-C-related chronic liver disease in Sweden. Scand J Gastroenterol 1997;32:175-8.
50. Zuckerman M, Hadjinicolaou C. Autoimmune hepatitis in children at Baragwanath hospital [abstract]. Hepatology 1996;23:I-86A.
51. Bayraktar Y, Bayraktar M, Gurakar A, et al. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases. Hepatogastroenterology 1997;44:417-25.
52. Duchini A, McHutchison JG, Pockros PJ. LKM-1 positive autoimmune hepatitis in the Western United States: a case series. Am J Gastroenterol 2000;95:3238-41.
53. Miyakawa H, Kako M, Nagai K, et al. HCV-RNA in type 2 autoimmune hepatitis. Am J Gastroenterol 1991;86:1688-9.
54. Nishioka M, Morshed SA, Kono K, et al. Frequency and significance of antibodies to P450IID6 protein in Japanese patients with chronic hepatitis C. J Hepatol 1997;26:992-1000.
55. Bittencourt PL, Goldberg AC, Cancado EL, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94:1906-13.
56. Czaja AJ, Kruger M, Santrach PJ, et al. Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol 1997;92:2197-200.
57. Esteban JI, Esteban R, Viladomiu L, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2:294-7.
58. Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991;338:277-80.
59. Lunel F, Abuaf N, Frangeul L, et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992;16:630-6.
60. Michel G, Ritter A, Gerken G, et al. Anti-GOR and hepatitis C in autoimmune liver diseases. Lancet 1992;339:267-9.
61. Strassburg CP, Manns MP. Autoimmune hepatitis versus viral hepatitis C. Liver 1995;15:225-32.
62. Yamamoto AM, Cresteil D, Homberg JC, et al. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and negative sera. Gastroenterology 1993; 104:1762-7.
63. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000;33:208-15.
64. Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993;105:1522-8.
65. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31:635-40.
66. Lohse AW, Gerken G, Mohr H, et al. Relation between autoimmune liver diseases and viral hepatitis: clinical and serological characteristics in 859 patients. Z Gastroenterol 1995;33:527-33.
67. Nishioka M, Morshed SA, Parveen S, et al. Antibodies to P4501ID6, SLA, PDH-E2 and BCKD-E2 in Japanese patients with chronic hepatitis. J Gastroenterol Hepatol 1997;12:862-8.
68. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96:1224-31.
69. Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology 1993;105:1502-7.
70. Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-23.
71. Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994;19:609-15.
72. Donaldson PT, Albertini RJ, Krawitt EL. Immunogenetic studies of autoimmune hepatitis and primary sclerosing cholangitis. In: Krawitt EL, Wiesner RH, Nishioka M, editors. Autoimmune liver diseases. 2nd edition. Amsterdam, Elsevier; 1998. pp. 141-165.
73. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigen DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-6.
74. Fainboim L, Velasco VCC, Marcos CY, et al. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB1*1301, a marker for pediatric autoimmune hepatitis. Hepatology 2001;33:1512-7.
75. Manns MP, Krüger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994;106: 1676-97.
76. McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999;53:255-63.
77. Opelz G, Vogten AJM, Summerskill WHJ, et al. HLA determinants in chronic active liver disease: possible relation of HLA-Dw3 to prognosis. Tissue Antigens 1977;9:36-40.
78. Strettell MDJ, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-35.
79. Seki T, Kiyosawa K, Inoko H, et al. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology 1990;12:1300-4.
80. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology 1992;103:1041-7.
81. Ota M, Seki T, Kiyosawa K, et al. A possible association between basic amino acids of position 13 of DRB1 chains and autoimmune hepatitis. Immunogenetics 1992;36:49-55.
82. Miyamori H, Kato Y, Kobayashi K, et al. HLA antigens in Japanese patients with primary biliary cirrhosis and autoimmune hepatitis. Digestion 1983;26:213-7.
83. Marcos Y, Fainboim HA, Capucchio M, et al. Two-locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis. Hepatology 1994;19:1371-4.
84. Fainboim L, Marcos Y, Pando M, et al. Chronic active autoimmune hepatitis in children. Strong association with a particular HLA-DR6 (DRB1*1301) haplotype. Hum Immunol 1994;41: 146-50.
85. Pando M, Larriba J, Fernandez GC, et al. Pediatric and adult forms of type 1 autoimmune hepatitis in Argentina: evidence for differential genetic predisposition. Hepatology 1999;30: 1374-80.
86. Goldberg AC, Bittencourt PL, Mougin B, et al. Analysis of HLA haplotypes in autoimmune hepatitis type 1: identifying the major susceptibility locus. Hum Immunol 2001;62:165-9.
87. Vázquez-Garcia MN, Aláez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-90.
88. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 2001;15:553-62.